Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial
dc.contributor.author | Hutchins, Laura E. | en_US |
dc.contributor.author | Fletcher, William S. | en_US |
dc.contributor.author | Smith, John W. | en_US |
dc.contributor.author | Liu, P. Y. | en_US |
dc.contributor.author | Urba, Walter J. | en_US |
dc.contributor.author | Sosman, Jeffrey A. | en_US |
dc.contributor.author | Margolin, Kim A. | en_US |
dc.contributor.author | Flaherty, Lawrence E. | en_US |
dc.contributor.author | Hersh, Evan M. | en_US |
dc.contributor.author | Sondak, Vernon K. | en_US |
dc.contributor.author | Weiss, Geoffrey R. | en_US |
dc.contributor.author | Unger, Joseph M. | en_US |
dc.date.accessioned | 2006-09-08T20:08:18Z | |
dc.date.available | 2006-09-08T20:08:18Z | |
dc.date.issued | 1999-05 | en_US |
dc.identifier.citation | Margolin, Kim A.; Liu, P. Y.; Unger, Joseph M.; Fletcher, William S.; Flaherty, Lawrence E.; Urba, Walter J.; Hersh, Evan M.; Hutchins, Laura E.; Sosman, Jeffrey A.; Smith, John W.; Weiss, Geoffrey R.; Sondak, Vernon K.; (1999). "Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial." Journal of Cancer Research and Clinical Oncology 125(5): 292-296. <http://hdl.handle.net/2027.42/42256> | en_US |
dc.identifier.issn | 0171-5216 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42256 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10359134&dopt=citation | en_US |
dc.description.abstract | The therapeutic benefit of adding interferon α (IFNα) to established single-agent and combination chemotherapy regimens for the treatment of metastatic melanoma has not been proven. We designed the present study to estimate the response rate of IFNα, dacarbazine, cisplatin and tamoxifen in patients who had not been treated with systemic therapy for advanced disease. Using a schedule similar to that which had previously been shown to favor IFNα plus dacarbazine over dacarbazine alone, we treated patients with an “induction” regimen of IFNα, 15 mU m −2 day −1 intravenously 5 days/week for 3 weeks. Following induction, schedules of IFNα, 5 mU m −2 day −1 subcutaneously three times a week, and tamoxifen, 10 mg orally twice a day, were begun. Dacarbazine, 250 mg m −2 day −1 and cisplatin 33 mg m −2 day −1 for 3 consecutive days were repeated every 4 weeks, and subcutaneous IFNα and oral tamoxifen were continued until the discontinuation of chemotherapy. We treated 25 patients (18 men and 7 women, median age 52 years) and observed only 1 objective response (response rate 4%, 95% confidence interval 0.1%–20%). The toxicities of the regimen consisted of moderate myelosuppression and constitutional side-effects. On the basis of the low antitumor activity of this regimen, we do not recommend it for further study or for use as standard therapy of metastatic melanoma. | en_US |
dc.format.extent | 81285 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Legacy | en_US |
dc.subject.other | Interferon | en_US |
dc.subject.other | Biochemotherapy | en_US |
dc.subject.other | Key Words Melanoma | en_US |
dc.title | Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, MI, | en_US |
dc.contributor.affiliationother | University of Arizona Cancer Center, Tucson, AZ, | en_US |
dc.contributor.affiliationother | University of Arkansas for Medical Science, Little Rock, AR, | en_US |
dc.contributor.affiliationother | Department of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010-3000 USA Tel.: +1 626-359 8111 (ext 2307) Fax: +1 626-301 8898, US | en_US |
dc.contributor.affiliationother | Columbia River CCOP, Portland, OR, | en_US |
dc.contributor.affiliationother | University of Illinois at Chicago, IL, | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, WA, USA, US | en_US |
dc.contributor.affiliationother | Wayne State University Medical Center, Detroit, MI, | en_US |
dc.contributor.affiliationother | Oregon Health Sciences University, Portland, OR, | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, WA, USA, US | en_US |
dc.contributor.affiliationother | Columbia River CCOP, Portland, OR, | en_US |
dc.contributor.affiliationother | University of Texas Health Science Center at San Antonio, TX, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 10359134 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42256/1/432-125-5-292_91250292.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s004320050276 | en_US |
dc.identifier.source | Journal of Cancer Research and Clinical Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.